| Field | Row 1 |
|---|---|
| adsh | 0001640334-25-000825 |
| cik | 1621221 |
| name | ARTELO BIOSCIENCES, INC. |
| sic | 2834 |
| countryba | US |
| stprba | CA |
| cityba | SOLANA BEACH |
| zipba | 92075 |
| bas1 | 505 LOMAS SANTA FE, SUITE 160 |
| bas2 | |
| baph | 858-925-7049 |
| countryma | US |
| stprma | CA |
| cityma | SOLANA BEACH |
| zipma | 92075 |
| mas1 | 505 LOMAS SANTA FE, SUITE 160 |
| mas2 | |
| countryinc | US |
| stprinc | NV |
| ein | 331220924 |
| former | REACTIVE MEDICAL INC. |
| changed | 20170207 |
| afs | 4-NON |
| wksi | 0 |
| fye | 1231 |
| form | 10-Q |
| period | 20250331 |
| fy | 2025 |
| fp | Q1 |
| filed | 20250513 |
| accepted | 2025-05-13 08:23:00.0 |
| prevrpt | 0 |
| detail | 1 |
| instance | artl_10q_htm.xml |
| nciks | 1 |
| aciks |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| cik | Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings. |
| name | Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date. |
| sic | Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business. |
| countryba | The ISO 3166-1 country of the registrant's business address. |
| stprba | The state or province of the registrant’s business address, if field countryba is US or CA. |
| cityba | The city of the registrant's business address. |
| zipba | The zip code of the registrant’s business address. |
| bas1 | The first line of the street of the registrant’s business address. |
| bas2 | The second line of the street of the registrant’s business address. |
| baph | The phone number of the registrant’s business address. |
| countryma | The ISO 3166-1 country of the registrant's mailing address. |
| stprma | The state or province of the registrant’s mailing address, if field countryma is US or CA. |
| cityma | The city of the registrant's mailing address. |
| zipma | The zip code of the registrant’s mailing address. |
| mas1 | The first line of the street of the registrant’s mailing address. |
| mas2 | The second line of the street of the registrant’s mailing address. |
| countryinc | The ISO 3166-1 country of incorporation for the registrant. |
| stprinc | The state or province of incorporation for the registrant, if countryinc is US or CA. |
| ein | Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States. |
| former | Most recent former name of the registrant, if any. |
| changed | Date of change from the former name, if any. |
| afs | Filer status with the SEC at the time of submission: 1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned. |
| wksi | Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement. |
| fye | Fiscal Year End Date, rounded to nearest month-end. |
| form | The submission type of the registrant’s filing. |
| period | Balance Sheet Date, rounded to nearest month-end. |
| fy | Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8). |
| fp | Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year. |
| filed | The date of the registrant’s filing with the Commission. |
| accepted | The acceptance date and time of the registrant’s filing with the Commission. |
| prevrpt | Previous Report – TRUE indicates that the submission information was subsequently amended. |
| detail | TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount). |
| instance | The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol. |
| nciks | Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing. |
| aciks | Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information. |
| adsh | ddate | tag | value | uom | qtrs | version | segments | coreg | footnote |
|---|---|---|---|---|---|---|---|---|---|
| 0001640334-25-000825 | 20250331 | Accumulated Other Comprehensive Income Loss Net Of Tax | -227000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Additional Paid In Capital | 53384000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20241231 | Advances From Investors | 0.0000 | USD | 0 | 0001640334-25-000825 | |||
| 0001640334-25-000825 | 20250331 | Assets Current | 1382000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Due To Related Parties | 5000.0000 | USD | 0 | 0001640334-25-000825 | Related Party Transactions By Related Party= Senior Vice President; | ||
| 0001640334-25-000825 | 20240331 | Earnings Per Share Diluted | -0.7800 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 5000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Increase Decrease In Advances From Investors | 0.0000 | USD | 1 | 0001640334-25-000825 | |||
| 0001640334-25-000825 | 20241231 | Liabilities And Stockholders Equity | 4698000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Liabilities Current | 2804000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Non Cash Transaction Initial Recognition Of The Right Of Use Asset And Lease Liability | 0.0000 | USD | 1 | 0001640334-25-000825 | |||
| 0001640334-25-000825 | 20240331 | Nonoperating Income Expense | 106000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Operating Lease Liability Current | 36000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Payments To Acquire Marketable Securities | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20241231 | Preferred Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20241231 | Preferred Stock Value | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Share Based Compensation | 74000.0000 | USD | 1 | us-gaap/2024 | Incentive Distribution Made To Managing Member Or General Partner= Research And Development; | ||
| 0001640334-25-000825 | 20240331 | Stock Issued During Period Value New Issues | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001640334-25-000825 | 20240331 | Weighted Average Number Of Diluted Shares Outstanding | 3197000.0000 | shares | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20241231 | Accounts Payable And Accrued Liabilities Current | 1676000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20241231 | Assets | 4698000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20241231 | Common Stock Shares Authorized | 50000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20241231 | Deferred Costs | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Fair Value Adjustments For Trading Marketable Securities | 106000.0000 | USD | 1 | 0001640334-25-000825 | |||
| 0001640334-25-000825 | 20250331 | General And Administrative Expense | 995000.0000 | USD | 1 | us-gaap/2024 | Incentive Distribution Made To Managing Member Or General Partner= General And Administrative; | ||
| 0001640334-25-000825 | 20241231 | Intangible Assets Net Excluding Goodwill | 2039000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20241231 | Liabilities Current | 1772000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Net Income Loss | -2372000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001640334-25-000825 | 20250331 | Operating Lease Liability Noncurrent | 59000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20241231 | Operating Lease Right Of Use Asset | 99000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Preferred Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Preferred Stock Value | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Profit Loss | -2372000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Research And Development Expense | 1384000.0000 | USD | 1 | us-gaap/2024 | Incentive Distribution Made To Managing Member Or General Partner= Research And Development; | ||
| 0001640334-25-000825 | 20240331 | Share Based Compensation | 139000.0000 | USD | 1 | us-gaap/2024 | Incentive Distribution Made To Managing Member Or General Partner= General And Administrative; | ||
| 0001640334-25-000825 | 20250331 | Shares Issued | 3281000.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001640334-25-000825 | 20231231 | Stockholders Equity | -203000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001640334-25-000825 | 20231231 | Stockholders Equity | -40310000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001640334-25-000825 | 20241231 | Stockholders Equity | -50136000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001640334-25-000825 | 20250331 | Stockholders Equity | -227000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001640334-25-000825 | 20250331 | Stockholders Equity | 53384000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001640334-25-000825 | 20250331 | Stockholders Equity | 3000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001640334-25-000825 | 20240331 | Stock Issued During Period Value New Issues | 55000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20241231 | Common Stock Value | 3000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Common Stock Value | 3000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Comprehensive Income Net Of Tax | -2483000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20241231 | Due To Related Parties | 1000.0000 | USD | 0 | 0001640334-25-000825 | Related Party Transactions By Related Party= Senior Vice President; | ||
| 0001640334-25-000825 | 20250331 | Due To Related Parties | 23000.0000 | USD | 0 | 0001640334-25-000825 | |||
| 0001640334-25-000825 | 20250331 | Increase Decrease In Deferred Offering Costs | 424000.0000 | USD | 1 | 0001640334-25-000825 | |||
| 0001640334-25-000825 | 20240331 | Increase Decrease In Operating Lease Liability | -8000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Net Cash Provided By Used In Financing Activities | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Net Income Loss | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001640334-25-000825 | 20250331 | Net Income Loss | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001640334-25-000825 | 20250331 | Net Income Loss | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001640334-25-000825 | 20240331 | Operating Expenses | 2589000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20241231 | Other Assets | 3000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Other Noncash Expense | 8000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Share Based Compensation | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001640334-25-000825 | 20240331 | Stockholders Equity | 52530000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001640334-25-000825 | 20240331 | Stock Issued During Period Shares New Issues | 39000.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001640334-25-000825 | 20250331 | Deferred Costs | 424000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20241231 | Due To Related Parties | 61000.0000 | USD | 0 | 0001640334-25-000825 | |||
| 0001640334-25-000825 | 20240331 | General And Administrative Expense | 1082000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Income Taxes Paid Net | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Net Cash Provided By Used In Operating Activities | -2942000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Net Cash Provided By Used In Operating Activities | -1597000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Net Gains Losses On Trading Marketable Securities | 0.0000 | USD | 1 | 0001640334-25-000825 | |||
| 0001640334-25-000825 | 20240331 | Net Income Loss | -2483000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Net Income Loss | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001640334-25-000825 | 20250331 | Nonoperating Income Expense | 7000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Other Comprehensive Income Loss Net Of Tax | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001640334-25-000825 | 20240331 | Payments To Acquire Marketable Securities | 481000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20241231 | Preferred Stock Shares Authorized | 416667.0000 | shares | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Proceeds From Issuance Of Common Stock | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Profit Loss | -2483000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Research And Development Expense | 1384000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Retained Earnings Accumulated Deficit | -52508000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Share Based Compensation | 213000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Share Based Compensation | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001640334-25-000825 | 20240331 | Share Based Compensation | 213000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001640334-25-000825 | 20240331 | Share Based Compensation | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001640334-25-000825 | 20250331 | Share Based Compensation | 192000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001640334-25-000825 | 20250331 | Share Based Compensation | 78000.0000 | USD | 1 | us-gaap/2024 | Incentive Distribution Made To Managing Member Or General Partner= Research And Development; | ||
| 0001640334-25-000825 | 20231231 | Stockholders Equity | 11752000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20241231 | Stockholders Equity | 2857000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20241231 | Stockholders Equity | 53192000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001640334-25-000825 | 20241231 | Accumulated Other Comprehensive Income Loss Net Of Tax | -202000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Advances From Investors | 236000.0000 | USD | 0 | 0001640334-25-000825 | |||
| 0001640334-25-000825 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -1592000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | General And Administrative Expense | 1082000.0000 | USD | 1 | us-gaap/2024 | Incentive Distribution Made To Managing Member Or General Partner= General And Administrative; | ||
| 0001640334-25-000825 | 20250331 | Income Taxes Paid Net | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Interest Income Other | 7000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Liabilities | 2863000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Net Cash Provided By Used In Financing Activities | 55000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Net Cash Provided By Used In Investing Activities | 1269000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Net Income Loss | -2372000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Net Income Loss | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001640334-25-000825 | 20250331 | Operating Income Loss | -2379000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Other Assets | 3000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Other Comprehensive Income Loss Net Of Tax | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Prepaid Expense And Other Assets Current | 212000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Share Based Compensation | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001640334-25-000825 | 20250331 | Share Based Compensation | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001640334-25-000825 | 20241231 | Stockholders Equity | 3000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001640334-25-000825 | 20250331 | Stockholders Equity | -52508000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001640334-25-000825 | 20250331 | Weighted Average Number Of Diluted Shares Outstanding | 3281000.0000 | shares | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Increase Decrease In Deferred Offering Costs | 0.0000 | USD | 1 | 0001640334-25-000825 | |||
| 0001640334-25-000825 | 20250331 | Assets | 3515000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20241231 | Assets Current | 2557000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20231231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 2815000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1195000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -1620000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20241231 | Common Stock Shares Issued | 3281032.0000 | shares | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20241231 | Common Stock Shares Outstanding | 3281032.0000 | shares | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20241231 | Due To Related Parties | 36000.0000 | USD | 0 | 0001640334-25-000825 | Related Party Transactions By Related Party= Influenced By A Director; | ||
| 0001640334-25-000825 | 20250331 | Due To Related Parties | 12000.0000 | USD | 0 | 0001640334-25-000825 | Related Party Transactions By Related Party= Influenced By A Director; | ||
| 0001640334-25-000825 | 20250331 | Fair Value Adjustments For Trading Marketable Securities | 0.0000 | USD | 1 | 0001640334-25-000825 | |||
| 0001640334-25-000825 | 20250331 | General And Administrative Expense | 995000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Income Tax Expense Benefit | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Increase Decrease In Accounts Payable And Accrued Liabilities | -624000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Increase Decrease In Accounts Payable Related Parties | 53000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Net Cash Provided By Used In Investing Activities | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Net Income Loss | -2483000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001640334-25-000825 | 20240331 | Non Cash Transaction Initial Recognition Of The Right Of Use Asset And Lease Liability | 111000.0000 | USD | 1 | 0001640334-25-000825 | |||
| 0001640334-25-000825 | 20241231 | Operating Lease Liability Current | 35000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | -25000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Other Comprehensive Income Loss Net Of Tax | -25000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Other Comprehensive Income Loss Net Of Tax | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001640334-25-000825 | 20250331 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Preferred Stock Shares Outstanding | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20231231 | Shares Issued | 3189000.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001640334-25-000825 | 20240331 | Shares Issued | 3228000.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001640334-25-000825 | 20240331 | Stockholders Equity | -42793000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001640334-25-000825 | 20241231 | Stockholders Equity | -202000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001640334-25-000825 | 20240331 | Stock Issued During Period Value New Issues | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001640334-25-000825 | 20240331 | Stock Issued During Period Value New Issues | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001640334-25-000825 | 20250331 | Accounts Payable And Accrued Liabilities Current | 2509000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20241231 | Additional Paid In Capital | 53192000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 2338000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 746000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20241231 | Common Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Common Stock Shares Issued | 3281032.0000 | shares | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Comprehensive Income Net Of Tax | -2397000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Due To Related Parties | 6000.0000 | USD | 0 | 0001640334-25-000825 | Related Party Transactions By Related Party= Controlled By A Director; | ||
| 0001640334-25-000825 | 20250331 | Earnings Per Share Diluted | -0.7200 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -2000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Income Tax Expense Benefit | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Increase Decrease In Advances From Investors | 236000.0000 | USD | 1 | 0001640334-25-000825 | |||
| 0001640334-25-000825 | 20250331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | -9000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Intangible Assets Net Excluding Goodwill | 2039000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Interest Income Other | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20241231 | Liabilities | 1841000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Liabilities And Stockholders Equity | 3515000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Operating Expenses | 2379000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Operating Income Loss | -2589000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20241231 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Proceeds From Issuance Of Common Stock | 55000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Proceeds From Sale And Maturity Of Marketable Securities | 1750000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Proceeds From Sale And Maturity Of Marketable Securities | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Research And Development Expense | 1507000.0000 | USD | 1 | us-gaap/2024 | Incentive Distribution Made To Managing Member Or General Partner= Research And Development; | ||
| 0001640334-25-000825 | 20241231 | Retained Earnings Accumulated Deficit | -50136000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Share Based Compensation | 192000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Share Based Compensation | 114000.0000 | USD | 1 | us-gaap/2024 | Incentive Distribution Made To Managing Member Or General Partner= General And Administrative; | ||
| 0001640334-25-000825 | 20241231 | Shares Issued | 3281000.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001640334-25-000825 | 20240331 | Stockholders Equity | 9537000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Stockholders Equity | 3000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001640334-25-000825 | 20250331 | Common Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Common Stock Shares Authorized | 50000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Common Stock Shares Outstanding | 3281032.0000 | shares | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20241231 | Due To Related Parties | 24000.0000 | USD | 0 | 0001640334-25-000825 | Related Party Transactions By Related Party= Controlled By A Director; | ||
| 0001640334-25-000825 | 20250331 | Increase Decrease In Accounts Payable And Accrued Liabilities | 800000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Increase Decrease In Accounts Payable Related Parties | -38000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Increase Decrease In Operating Lease Liability | -8000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | -5000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Interest Paid Net | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Interest Paid Net | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Net Gains Losses On Trading Marketable Securities | 106000.0000 | USD | 1 | 0001640334-25-000825 | |||
| 0001640334-25-000825 | 20240331 | Net Income Loss | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001640334-25-000825 | 20250331 | Operating Lease Liability Current | 36000.0000 | USD | 0 | us-gaap/2024 | Finite Lived Intangible Assets By Major Class= Lease; | ||
| 0001640334-25-000825 | 20241231 | Operating Lease Liability Noncurrent | 69000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Operating Lease Liability Noncurrent | 59000.0000 | USD | 0 | us-gaap/2024 | Finite Lived Intangible Assets By Major Class= Lease; | ||
| 0001640334-25-000825 | 20250331 | Operating Lease Right Of Use Asset | 91000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Other Comprehensive Income Loss Net Of Tax | -25000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001640334-25-000825 | 20250331 | Other Comprehensive Income Loss Net Of Tax | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001640334-25-000825 | 20240331 | Other Noncash Expense | 8000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20250331 | Preferred Stock Shares Authorized | 416667.0000 | shares | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20241231 | Preferred Stock Shares Outstanding | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20241231 | Prepaid Expense And Other Assets Current | 219000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Research And Development Expense | 1507000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Share Based Compensation | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001640334-25-000825 | 20231231 | Stockholders Equity | 52262000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001640334-25-000825 | 20231231 | Stockholders Equity | 3000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001640334-25-000825 | 20240331 | Stockholders Equity | -203000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001640334-25-000825 | 20250331 | Stockholders Equity | 652000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001640334-25-000825 | 20240331 | Stock Issued During Period Value New Issues | 55000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| ddate | The end date for the data value, rounded to the nearest month end. |
| qtrs | The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value. |
| uom | The unit of measure for the value. |
| segments | Tags used to represent axis and member reporting. |
| coreg | If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity. |
| value | The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point. |
| footnote | The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank. |
| tag | version | custom | abstract | datatype | iord | crdr | tlabel | doc |
|---|---|---|---|---|---|---|---|---|
| Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets, Current | Amount of asset recognized for present right to economic benefit, classified as current. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents | Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Operating Lease Liability Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Current | Present value of lessee's discounted obligation for lease payments from operating lease, classified as current. |
| Due To Related Parties | 0001640334-25-000825 | 1 | 0 | monetary | I | C | Due to related parties | Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer). For unclassified balance sheets, represents the total of such liabilities. |
| Accounts Payable And Accrued Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accounts Payable and Accrued Liabilities, Current | Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. |
| Comprehensive Income Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. |
| Advances From Investors | 0001640334-25-000825 | 1 | 0 | monetary | I | C | Advances from investors | |
| Liabilities | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities | Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. |
| Liabilities And Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities and Equity | Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. |
| Other Noncash Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Other Noncash Expense | Amount of expense or loss included in net income that result in no cash flow, classified as other. |
| Retained Earnings Accumulated Deficit | us-gaap/2024 | 0 | 0 | monetary | I | C | Retained Earnings (Accumulated Deficit) | Amount of accumulated undistributed earnings (deficit). |
| Increase Decrease In Advances From Investors | 0001640334-25-000825 | 1 | 0 | monetary | D | D | [Advances from investors] | |
| Additional Paid In Capital | us-gaap/2024 | 0 | 0 | monetary | I | C | Additional Paid in Capital | Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. |
| Common Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Common Stock, Par or Stated Value Per Share | Face amount or stated value per share of common stock. | |
| Common Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Outstanding | Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. | |
| Income Tax Expense Benefit | us-gaap/2024 | 0 | 0 | monetary | D | D | Income Tax Expense (Benefit) | Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. |
| Net Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss) Attributable to Parent | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. |
| Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Attributable to Parent | Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. |
| Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Diluted | The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. | |
| Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | I | C | Accumulated Other Comprehensive Income (Loss), Net of Tax | Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. |
| Assets | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets | Amount of asset recognized for present right to economic benefit. |
| Common Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Issued | Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. | |
| Earnings Per Share Diluted | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Diluted | The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | 0 | 0 | monetary | D | D | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations | Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Operating Lease Right Of Use Asset | us-gaap/2024 | 0 | 0 | monetary | I | D | Operating Lease, Right-of-Use Asset | Amount of lessee's right to use underlying asset under operating lease. |
| Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Shares, Issued | Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. | |
| Income Taxes Paid Net | us-gaap/2024 | 0 | 0 | monetary | D | C | Income Taxes Paid, Net | Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. |
| Fair Value Adjustments For Trading Marketable Securities | 0001640334-25-000825 | 1 | 0 | monetary | D | C | [Net change in fair value of trading marketable securities] | |
| Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities, Current | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax | Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. |
| Preferred Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Issued | Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. | |
| Proceeds From Sale And Maturity Of Marketable Securities | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Sale and Maturity of Marketable Securities | The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period. |
| Share Based Compensation | us-gaap/2024 | 0 | 0 | monetary | D | D | Share-Based Payment Arrangement, Noncash Expense | Amount of noncash expense for share-based payment arrangement. |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Prepaid Expense and Other Assets | Amount of increase (decrease) in prepaid expenses, and assets classified as other. |
| Nonoperating Income Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Nonoperating Income (Expense) | The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). |
| Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Net of Tax | Amount after tax and reclassification adjustments of other comprehensive income (loss). |
| Preferred Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Preferred Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Profit Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. |
| Common Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Common Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Intangible Assets Net Excluding Goodwill | us-gaap/2024 | 0 | 0 | monetary | I | D | Intangible Assets, Net (Excluding Goodwill) | Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. |
| Net Cash Provided By Used In Operating Activities | us-gaap/2024 | 0 | 0 | monetary | D | Net Cash Provided by (Used in) Operating Activities | Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. | |
| Operating Expenses | us-gaap/2024 | 0 | 0 | monetary | D | D | Operating Expenses | Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. |
| Operating Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Operating Income (Loss) | The net result for the period of deducting operating expenses from operating revenues. |
| Prepaid Expense And Other Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Prepaid Expense and Other Assets, Current | Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. |
| General And Administrative Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | General and Administrative Expense | The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. |
| Increase Decrease In Accounts Payable Related Parties | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accounts Payable, Related Parties | The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence. |
| Research And Development Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Research and Development Expense | Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. |
| Stock Issued During Period Shares New Issues | us-gaap/2024 | 0 | 0 | shares | D | Stock Issued During Period, Shares, New Issues | Number of new stock issued during the period. | |
| Interest Income Other | us-gaap/2024 | 0 | 0 | monetary | D | C | Interest Income, Other | Amount of interest income earned from interest bearing assets classified as other. |
| Increase Decrease In Deferred Offering Costs | 0001640334-25-000825 | 1 | 0 | monetary | D | C | [Deferred offering costs] | |
| Non Cash Transaction Initial Recognition Of The Right Of Use Asset And Lease Liability | 0001640334-25-000825 | 1 | 0 | monetary | D | C | Initial recognition of the right-of-use asset and lease liability | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | 0 | 0 | monetary | D | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Common Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares Authorized | The maximum number of common shares permitted to be issued by an entity's charter and bylaws. | |
| Increase Decrease In Operating Lease Liability | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Operating Lease Liability | Amount of increase (decrease) in obligation for operating lease. |
| Net Cash Provided By Used In Financing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Financing Activities | Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. |
| Preferred Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Preferred Stock, Par or Stated Value Per Share | Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. | |
| Interest Paid Net | us-gaap/2024 | 0 | 0 | monetary | D | C | Interest Paid, Excluding Capitalized Interest, Operating Activities | Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. |
| Deferred Costs | us-gaap/2024 | 0 | 0 | monetary | I | D | Deferred Costs, Noncurrent | Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent. |
| Increase Decrease In Accounts Payable And Accrued Liabilities | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accounts Payable and Accrued Liabilities | The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. |
| Net Cash Provided By Used In Investing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Investing Activities | Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. |
| Payments To Acquire Marketable Securities | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Marketable Securities | Amount of cash outflow for purchase of marketable security. |
| Preferred Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Authorized | The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. | |
| Preferred Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Outstanding | Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. | |
| Proceeds From Issuance Of Common Stock | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Issuance of Common Stock | The cash inflow from the additional capital contribution to the entity. |
| Stock Issued During Period Value New Issues | us-gaap/2024 | 0 | 0 | monetary | D | C | Stock Issued During Period, Value, New Issues | Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. |
| Operating Lease Liability Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Noncurrent | Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. |
| Other Assets | us-gaap/2024 | 0 | 0 | monetary | I | D | Other Assets | Amount of assets classified as other. |
| Net Gains Losses On Trading Marketable Securities | 0001640334-25-000825 | 1 | 0 | monetary | D | C | Net change in fair value of trading marketable securities |
| Field Name | Field Description |
|---|---|
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| custom | 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns. |
| abstract | 1 if the tag is not used to represent a numeric fact. |
| datatype | If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag. |
| iord | If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration. |
| crdr | If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL. |
| tlabel | If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here. |
| doc | The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL. |
| adsh | report | line | stmt | inpth | rfile | tag | version | plabel | negating |
|---|---|---|---|---|---|---|---|---|---|
| 0001640334-25-000825 | 6 | 13 | CF | 0 | H | Increase Decrease In Operating Lease Liability | us-gaap/2024 | Fixed cash payments related to operating leases | 0 |
| 0001640334-25-000825 | 6 | 14 | CF | 0 | H | Net Cash Provided By Used In Operating Activities | us-gaap/2024 | Net cash used in operating activities | 0 |
| 0001640334-25-000825 | 6 | 16 | CF | 0 | H | Payments To Acquire Marketable Securities | us-gaap/2024 | Investment in trading marketable securities | 1 |
| 0001640334-25-000825 | 6 | 17 | CF | 0 | H | Proceeds From Sale And Maturity Of Marketable Securities | us-gaap/2024 | Proceeds from disposition of marketable securities | 0 |
| 0001640334-25-000825 | 6 | 18 | CF | 0 | H | Net Cash Provided By Used In Investing Activities | us-gaap/2024 | Net cash provided by investing activities | 0 |
| 0001640334-25-000825 | 6 | 20 | CF | 0 | H | Proceeds From Issuance Of Common Stock | us-gaap/2024 | Proceeds from issuance of common shares for cash, net | 0 |
| 0001640334-25-000825 | 6 | 21 | CF | 0 | H | Net Cash Provided By Used In Financing Activities | us-gaap/2024 | Net cash provided by financing activities | 0 |
| 0001640334-25-000825 | 6 | 22 | CF | 0 | H | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Effect of exchange rate changes on cash | 0 |
| 0001640334-25-000825 | 6 | 23 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | Net change in cash and cash equivalents | 0 |
| 0001640334-25-000825 | 6 | 24 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Cash and cash equivalents - beginning of period | 0 |
| 0001640334-25-000825 | 6 | 25 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Cash and cash equivalents - end of period | 0 |
| 0001640334-25-000825 | 6 | 27 | CF | 0 | H | Interest Paid Net | us-gaap/2024 | Cash paid for interest | 0 |
| 0001640334-25-000825 | 6 | 28 | CF | 0 | H | Income Taxes Paid Net | us-gaap/2024 | Cash paid for income taxes | 0 |
| 0001640334-25-000825 | 6 | 30 | CF | 0 | H | Non Cash Transaction Initial Recognition Of The Right Of Use Asset And Lease Liability | 0001640334-25-000825 | Initial recognition of the right-of-use asset and lease liability | 0 |
| 0001640334-25-000825 | 2 | 3 | BS | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Cash and cash equivalents | 0 |
| 0001640334-25-000825 | 2 | 4 | BS | 0 | H | Prepaid Expense And Other Assets Current | us-gaap/2024 | Prepaid expenses and other current assets | 0 |
| 0001640334-25-000825 | 2 | 5 | BS | 0 | H | Deferred Costs | us-gaap/2024 | Deferred offering costs | 0 |
| 0001640334-25-000825 | 2 | 6 | BS | 0 | H | Assets Current | us-gaap/2024 | Total Current Assets | 0 |
| 0001640334-25-000825 | 2 | 7 | BS | 0 | H | Operating Lease Right Of Use Asset | us-gaap/2024 | Operating lease right-of-use assets | 0 |
| 0001640334-25-000825 | 2 | 8 | BS | 0 | H | Intangible Assets Net Excluding Goodwill | us-gaap/2024 | Intangible asset | 0 |
| 0001640334-25-000825 | 2 | 9 | BS | 0 | H | Other Assets | us-gaap/2024 | Other assets | 0 |
| 0001640334-25-000825 | 2 | 10 | BS | 0 | H | Assets | us-gaap/2024 | TOTAL ASSETS | 0 |
| 0001640334-25-000825 | 2 | 12 | BS | 0 | H | Accounts Payable And Accrued Liabilities Current | us-gaap/2024 | Accounts payable and accrued liabilities | 0 |
| 0001640334-25-000825 | 2 | 13 | BS | 0 | H | Due To Related Parties | 0001640334-25-000825 | Due to related parties | 0 |
| 0001640334-25-000825 | 2 | 14 | BS | 0 | H | Operating Lease Liability Current | us-gaap/2024 | Operating lease liabilities - current portion | 0 |
| 0001640334-25-000825 | 2 | 15 | BS | 0 | H | Advances From Investors | 0001640334-25-000825 | Advances from investors | 0 |
| 0001640334-25-000825 | 2 | 16 | BS | 0 | H | Liabilities Current | us-gaap/2024 | Total Current Liabilities | 0 |
| 0001640334-25-000825 | 2 | 17 | BS | 0 | H | Operating Lease Liability Noncurrent | us-gaap/2024 | Operating Lease, Liability, Noncurrent | 0 |
| 0001640334-25-000825 | 2 | 18 | BS | 0 | H | Liabilities | us-gaap/2024 | TOTAL LIABILITIES | 0 |
| 0001640334-25-000825 | 2 | 20 | BS | 0 | H | Preferred Stock Value | us-gaap/2024 | Preferred Stock, par value $0.001, 416,667 shares authorized, 0 shares issued and outstanding as of March 31, 2025 and December 31, 2024 | 0 |
| 0001640334-25-000825 | 2 | 21 | BS | 0 | H | Common Stock Value | us-gaap/2024 | Common Stock, par value $0.001, 50,000,000 shares authorized and 3,281,032 shares issued and outstanding as of March 31, 2025, and December 31, 2024 | 0 |
| 0001640334-25-000825 | 2 | 22 | BS | 0 | H | Additional Paid In Capital | us-gaap/2024 | Additional paid-in capital | 0 |
| 0001640334-25-000825 | 2 | 23 | BS | 0 | H | Retained Earnings Accumulated Deficit | us-gaap/2024 | Accumulated deficit | 0 |
| 0001640334-25-000825 | 2 | 24 | BS | 0 | H | Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | Accumulated other comprehensive loss | 0 |
| 0001640334-25-000825 | 2 | 25 | BS | 0 | H | Stockholders Equity | us-gaap/2024 | TOTAL STOCKHOLDERS' EQUITY | 0 |
| 0001640334-25-000825 | 2 | 26 | BS | 0 | H | Liabilities And Stockholders Equity | us-gaap/2024 | TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | 0 |
| 0001640334-25-000825 | 3 | 1 | BS | 1 | H | Preferred Stock Par Or Stated Value Per Share | us-gaap/2024 | Preferred stock, par value | 0 |
| 0001640334-25-000825 | 3 | 2 | BS | 1 | H | Preferred Stock Shares Authorized | us-gaap/2024 | Preferred stock, shares authorized | 0 |
| 0001640334-25-000825 | 3 | 3 | BS | 1 | H | Preferred Stock Shares Issued | us-gaap/2024 | Preferred stock, shares issued | 0 |
| 0001640334-25-000825 | 3 | 4 | BS | 1 | H | Preferred Stock Shares Outstanding | us-gaap/2024 | Preferred stock, shares outstanding | 0 |
| 0001640334-25-000825 | 3 | 5 | BS | 1 | H | Common Stock Par Or Stated Value Per Share | us-gaap/2024 | Common stock, par value | 0 |
| 0001640334-25-000825 | 3 | 6 | BS | 1 | H | Common Stock Shares Authorized | us-gaap/2024 | Common stock, shares authorized | 0 |
| 0001640334-25-000825 | 3 | 7 | BS | 1 | H | Common Stock Shares Issued | us-gaap/2024 | Common stock, shares issued | 0 |
| 0001640334-25-000825 | 3 | 8 | BS | 1 | H | Common Stock Shares Outstanding | us-gaap/2024 | Common Stock, Shares Outstanding | 0 |
| 0001640334-25-000825 | 4 | 2 | IS | 0 | H | General And Administrative Expense | us-gaap/2024 | General and administrative | 0 |
| 0001640334-25-000825 | 4 | 3 | IS | 0 | H | Research And Development Expense | us-gaap/2024 | Research and development | 0 |
| 0001640334-25-000825 | 4 | 4 | IS | 0 | H | Operating Expenses | us-gaap/2024 | Total Operating Expenses | 0 |
| 0001640334-25-000825 | 4 | 5 | IS | 0 | H | Operating Income Loss | us-gaap/2024 | Loss from Operations | 0 |
| 0001640334-25-000825 | 4 | 7 | IS | 0 | H | Net Gains Losses On Trading Marketable Securities | 0001640334-25-000825 | Net change in fair value of trading marketable securities | 0 |
| 0001640334-25-000825 | 4 | 8 | IS | 0 | H | Interest Income Other | us-gaap/2024 | Interest income | 0 |
| 0001640334-25-000825 | 4 | 9 | IS | 0 | H | Nonoperating Income Expense | us-gaap/2024 | Total other income | 0 |
| 0001640334-25-000825 | 4 | 10 | IS | 0 | H | Income Tax Expense Benefit | us-gaap/2024 | Provision for income taxes | 0 |
| 0001640334-25-000825 | 4 | 11 | IS | 0 | H | Net Income Loss | us-gaap/2024 | NET LOSS | 0 |
| 0001640334-25-000825 | 4 | 13 | IS | 0 | H | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | us-gaap/2024 | Foreign currency translation adjustments | 0 |
| 0001640334-25-000825 | 4 | 14 | IS | 0 | H | Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | Total Other Comprehensive Loss | 0 |
| 0001640334-25-000825 | 4 | 15 | IS | 0 | H | Comprehensive Income Net Of Tax | us-gaap/2024 | TOTAL COMPREHENSIVE LOSS | 0 |
| 0001640334-25-000825 | 4 | 16 | IS | 0 | H | Earnings Per Share Diluted | us-gaap/2024 | Basic and Diluted Loss per Common Share | 0 |
| 0001640334-25-000825 | 4 | 17 | IS | 0 | H | Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | Basic and Diluted Weighted Average Common Shares Outstanding | 0 |
| 0001640334-25-000825 | 5 | 9 | EQ | 0 | H | Shares Issued | us-gaap/2024 | Balance, shares | 0 |
| 0001640334-25-000825 | 5 | 10 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | Balance, amount | 0 |
| 0001640334-25-000825 | 5 | 11 | EQ | 0 | H | Stock Issued During Period Shares New Issues | us-gaap/2024 | Common shares issued for cash, shares | 0 |
| 0001640334-25-000825 | 5 | 12 | EQ | 0 | H | Stock Issued During Period Value New Issues | us-gaap/2024 | Common shares issued for cash, amount | 0 |
| 0001640334-25-000825 | 5 | 13 | EQ | 0 | H | Share Based Compensation | us-gaap/2024 | Stock based compensation | 0 |
| 0001640334-25-000825 | 5 | 14 | EQ | 0 | H | Net Income Loss | us-gaap/2024 | Net loss for the period | 0 |
| 0001640334-25-000825 | 5 | 15 | EQ | 0 | H | Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | Other comprehensive loss | 0 |
| 0001640334-25-000825 | 5 | 16 | EQ | 0 | H | Shares Issued | us-gaap/2024 | Balance, shares | 0 |
| 0001640334-25-000825 | 5 | 17 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | Balance, amount | 0 |
| 0001640334-25-000825 | 6 | 2 | CF | 0 | H | Profit Loss | us-gaap/2024 | Net loss | 0 |
| 0001640334-25-000825 | 6 | 4 | CF | 0 | H | Share Based Compensation | us-gaap/2024 | Stock-based compensation | 0 |
| 0001640334-25-000825 | 6 | 5 | CF | 0 | H | Fair Value Adjustments For Trading Marketable Securities | 0001640334-25-000825 | Net change in fair value of trading marketable securities | 1 |
| 0001640334-25-000825 | 6 | 6 | CF | 0 | H | Other Noncash Expense | us-gaap/2024 | Non-cash lease expense | 0 |
| 0001640334-25-000825 | 6 | 8 | CF | 0 | H | Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | Prepaid expenses and other current assets | 1 |
| 0001640334-25-000825 | 6 | 9 | CF | 0 | H | Increase Decrease In Deferred Offering Costs | 0001640334-25-000825 | Deferred offering costs | 1 |
| 0001640334-25-000825 | 6 | 10 | CF | 0 | H | Increase Decrease In Accounts Payable And Accrued Liabilities | us-gaap/2024 | Accounts payable and accrued liabilities | 0 |
| 0001640334-25-000825 | 6 | 11 | CF | 0 | H | Increase Decrease In Accounts Payable Related Parties | us-gaap/2024 | Accounts payable - related parties | 0 |
| 0001640334-25-000825 | 6 | 12 | CF | 0 | H | Increase Decrease In Advances From Investors | 0001640334-25-000825 | Advances from investors | 0 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| report | Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site. |
| line | Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived. |
| stmt | The financial statement location to which the value of the “report” field pertains. |
| inpth | Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700. |
| rfile | The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file. |
| tag | The tag chosen by the filer for this line item. |
| version | The taxonomy identifier if the tag is a standard tag, otherwise adsh. |
| plabel | The text presented on the line item, also known as a “preferred” label. |
| negating | Flag to indicate whether the plabel is negating. |